BioWorld

Nov. 13, 2003

View Archived Issues

As Expected, VaxGen's Second AidsVax Phase III In HIV Misses

VaxGen Inc.'s investigational vaccine for the prevention of HIV infection failed to hit primary or secondary endpoints in a Phase III trial conducted in Thailand. (BioWorld Today) Read More

YM Licenses European Rights To Cancer Drug In $30M Deal

Read More

In Seawater, Vibrio cholerae Form Calcium-Dependent Biofilms In Order To Survive

Read More

With Phase III Ongoing, Repligen Presents Preclinical Secretin Data

Read More

Other News To Note

Read More